Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Eur J Pharm Biopharm ; 179: 221-231, 2022 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-36122783

RESUMEN

The objective of this study was to obtain optimized nanostructured lipid carriers (NLC) functionalized with chitosan containing chloroaluminum phthalocyanine (ClAlPc) as a photosensitizer. Initially, the optimization of the preparation method of the NLC was performed, where the influence of different surfactants such as PVA and Tween 80, as well as different solid lipids such as stearic acid and Glycerol Monostearate (GM) was evaluated. The formulation containing GM and PVA (NLC10) was considered promising. Following, by the adsorption method (NLC10q), the formulation was functionalized with chitosan and characterized. NLC10 and NLC10q presented sizes of 131.5 and 231.5 nm, and ZP of -24.30 and + 19.96 mV, respectively. The encapsulation efficiency of NLC10q was 96 %, higher than NLC10 (79 %). The formulations were able to promote significant cutaneous retention of ClAlPc, after 2 h and 4 h of the study, and showed to be non-toxic to fibroblasts (biocompatible). PDT in BF16-F10 melanoma resulted in reduced cell viability to 70 % and 50 % for NLC10 and NLCq, respectively. In view of the results obtained, NLC showed to be promising in the treatment of skin cancer through PDT. NLC10q showed higher encapsulation efficiency and stability than NLC10, but, contrary to what was expected, it presented lower photodynamic efficiency.


Asunto(s)
Quitosano , Nanoestructuras , Fotoquimioterapia , Neoplasias Cutáneas , Portadores de Fármacos , Glicerol , Humanos , Indoles , Compuestos Organometálicos , Tamaño de la Partícula , Fotoquimioterapia/métodos , Fármacos Fotosensibilizantes , Polisorbatos , Neoplasias Cutáneas/tratamiento farmacológico , Tensoactivos
2.
Colloids Surf B Biointerfaces ; 188: 110739, 2020 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-31901623

RESUMEN

This study aims to develop in situ microemulsion-gel (ME-Gel) obtained from hydroxypropyl methylcellulose (HPMC) films for transdermal administration of Zidovudine (AZT). Firstly, HPMC films containing propylene glycol (PG) and eucalyptus oil (EO) were obtained and characterized. Later, a pseudo-ternary phase diagram composed of water, EO, tween 80 and PG was obtained and one microemulsion (ME) with a similar proportion of the film components was obtained. ME was transformed in ME-Gel by the incorporation of HPMC. Finally, HPMC films were hydrated with Tween 80 solution to yield in situ ME-Gel and its effect on AZT skin permeation was compared with HPMC film hydrated with water (F5hyd). The results showed that the ME and ME-Gel presented a droplet size of 16.79 and 122.13 µm, respectively, polydispersity index (PDI) < 0.39 and pH between 5.10 and 5.40. The incorporation of HPMC resulted in viscosity about 2 times higher than the use of ME. The presence of AZT did not alter the formulation properties. The in situ ME-Gel promoted a two-fold increase in the permeated amount of AZT compared to F5hyd. The results suggest that it was possible to obtain an ME-Gel in situ from HPMC films and that its effect on transdermal permeation of AZT was significant.


Asunto(s)
Metilcelulosa/química , Profármacos/química , Zidovudina/química , Administración Cutánea , Animales , Emulsiones/administración & dosificación , Emulsiones/química , Emulsiones/metabolismo , Aceite de Eucalipto/administración & dosificación , Aceite de Eucalipto/química , Aceite de Eucalipto/metabolismo , Geles/administración & dosificación , Geles/química , Geles/metabolismo , Masculino , Metilcelulosa/administración & dosificación , Metilcelulosa/metabolismo , Tamaño de la Partícula , Profármacos/administración & dosificación , Profármacos/metabolismo , Propilenglicol/administración & dosificación , Propilenglicol/química , Propilenglicol/metabolismo , Ratas , Ratas Wistar , Piel/química , Piel/metabolismo , Absorción Cutánea , Propiedades de Superficie , Zidovudina/administración & dosificación , Zidovudina/metabolismo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA